Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellerant Therapeutics, Inc.

Latest From Cellerant Therapeutics, Inc.

Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy

Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.

Business Strategies Deals

FDA eyes Amgen, Genzyme drugs for radiological/nuclear MCMs

While the bombs that were triggered by terrorists on 15 April in Boston did not contain radioactive materials, in the wake of that disaster, which demonstrated the ease at which an explosive device could be placed in a crowd unnoticed, and the ongoing threat from North Korea, the FDA is convening its first-ever advisory committee meeting to consider medical countermeasures (MCM) for use in the radiological/nuclear incident setting on 3 May.

Metabolic Disorders Cardiovascular

Cellerant lassos $36.4M in new BARDA funds for radiation drug

California biotech Cellerant Therapeutics garnered $36.4 million under an option exercised by the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development of CLT-008, an investigational first-in-class, allogeneic, cell-based therapy, as a treatment for acute radiation syndrome (ARS).

Cardiovascular Blood & Coagulation Disorders

US BARDA awards $56.3 million to advance radiation injury treatments

Araim Pharmaceuticals, Cellerant Therapeutics, Neumedicines, RxBio and the University of Arkansas were awarded a total of $56.3 million by the US Biomedical Advanced Research and Development Authority (BARDA) to develop new therapies to treat bone marrow, gastrointestinal, lung and skin injuries associated with acute radiation syndrome (ARS) caused by exposure to high doses of radiation, such as after denotation of an improvised nuclear device.

Cardiovascular Metabolic Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies